User:Mr. Ibrahem/Obinutuzumab

Obinutuzumab, previously known as afutuzumab, is a medication used for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It is used in CLL when fludarabine cannot be used. It is given by gradual injection into a vein.

Common side effects include upper respiratory tract infection, pneumonia, urinary tract infection, shingles, diarrhea, pain, trouble sleeping, hair loss, fever, low platelets, and low white blood cells. Other side effects may include progressive multifocal leukoencephalopathy and hepatitis B reactivation. It is a monoclonal antibody that attaches to CD20 and directs the immune system there.

Obinutuzumab was approved for medical use in the United States in 2013 and Europe in 2014. In the United Kingdom it costs the NHS about £3,300 per 1 gram vial as of 2021. This amount in the United States costs about 7,200 USD.